検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1941 : Li-7  update : 2024/01/30
細胞特性(Comment:英)Human hepatoma cell line. This cell line was established from nude mouse xenograft tumor (Dr. Hirohashi., National Cancer Center, Tokyo) by Tanno, H. (Tohoku Univ., 1st Surg). AFP producing. TKG0368 (Deposited from Tohoku Univ.).
細胞特性(日)ヒト肝臓癌由来細胞株。AFP産生。ヌードマウスへの移植にて樹立された株。 TKG0368 (東北大学医用細胞資源センターからの寄託)。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Obinata, Masuo
樹立者 Tanno, H. (Tohoku Univ., 1st Surg)
寄託日 2004
元の細胞 TKG0368
動物種 _human < Mammals
属名 Homo
種名 sapiens
性別 Male
45 years
採取組織 liver
病名 Hepatoma
細胞分類 cancer
入手歴 Cell Resource Center for Biomedical Research, Tohoku University(TKG0368)
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_3840
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 RPMI1640 + 10% FBS
抗生物質 Free
継代方法 (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : once/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
ウィルス(HBV) (-)
ウィルス(HCV) (-)
アイソザイム検査 LD, NP
染色体検査 57-64(50) : 57(8),58(9),59(11),60(2),61(3),62(12)/
個体識別検査 OK
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 0件
Reference(日) 0件
利用者成果(英) 35件
利用者成果(日) 0件

トップへページトップへ
Reference(英)

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
21642  Saengboonmee C, Thithuan K, Mahalapbutr P, Taebprakhon C, Aman A, Rungrotmongkol T, Kamkaew A, Schevenels FT, Chompupong T, Wongkham S, Lekphrom R.  Anti-proliferative Effects of Pinocembrin Isolated From Anomianthus dulcis on Hepatocellular Carcinoma Cells.  Integr Cancer Ther  2024  23:15347354241237519  PubMed ID: 38462928   DOI: 10.1177/15347354241237519
21726  Seyama Y, Sudo K, Yamada T, Tsuchiya K, Nakamura Y.  Ascorbic acid predominantly kills cancer stem cell-like cells in the hepatocellular carcinoma cell line Li-7 and is more effective at low cell density and in small spheroids  Biochem Biophys Res Commun  2024  May 21:709:149816  PubMed ID: 38547607   DOI: 10.1016/j.bbrc.2024.149816
19832  Rialdi A, Duffy M, Scopton AP, Fonseca F, Zhao JN, Schwarz M, Molina-Sanchez P, Mzoughi S, Arceci E, Abril-Fornaguera J, Meadows A, Ruiz de Galarreta M, Torre D, Reyes K, Lim YT, Rosemann F, Khan ZM, Mohammed K, Wang X, Yu X, Lakshmanan M, Rajarethinam R, Tan SY, Jin J, Villanueva A, Michailidis E, De Jong YP, Rice CM, Marazzi I, Hasson D, Llovet JM, Sobota RM, Lujambio A, Guccione E, Dar AC.  WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma  Nat Cancer  2023  4(8):1157-1175.  PubMed ID: 37537299   DOI: 10.1038/s43018-023-00609-9
19847  Seyama Y, Sudo K, Hirose S, Hamano Y, Yamada T, Hiroyama T, Sasaki R, Hirai MY, Hyodo I, Tsuchiya K, Nakamura Y.  Identification of a gene set that maintains tumorigenicity of the hepatocellular carcinoma cell line Li-7  Hum Cell  2023  36(6):2074-2086  PubMed ID: 37610679   DOI: 10.1007/s13577-023-00967-7
21247  Subbiah V, Sahai V, Maglic D, Bruderek K, Toure BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schonherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB.  RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations.  Cancer Discov  2023    PubMed ID: 37270847   DOI: 10.1158/2159-8290.CD-23-0475
20482  Bolatkan A, Asada K, Kaneko S, Suvarna K, Ikawa N, Machino H, Komatsu M, Shiina S, Hamamoto R.  Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules.  Int J Oncol  2022  60(1)  PubMed ID: 34913069   DOI: 10.3892/ijo.2021.5294
20679  Furuke H, Konishi H, Arita T, Kataoka S, Shibamoto J, Takabatake K, Takaki W, Shimizu H, Yamamoto Y, Morimura R, Komatsu S, Shiozaki A, Ikoma H, Otsuji E.  miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway.  Int J Mol Med  2022  49(6)  PubMed ID: 35485281   DOI: 10.3892/ijmm.2022.5139
16500  Hamaya S, Fujihara S, Iwama H, Fujita K, Shi T, Nakabayashi R, Mizuo T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Tani J, Morishita A, Kobara H, Ono M, Himoto T, Masaki T.  Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells  Anticancer Res  2022  42(3):1263-1275  PubMed ID: 35220216   DOI: 10.21873/anticanres.15593
16740  Itoh G, Takagane K, Fukushi Y, Kuriyama S, Umakoshi M, Goto A, Yanagihara K, Yashiro M, Tanaka M.  Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression  Mol Oncol  2022  16(1):166-187  PubMed ID: 34379869   DOI: 10.1002/1878-0261.13077
12538  Kaneya Y, Takata H, Wada R, Kure S, Ishino K, Kudo M, Kondo R, Taniai N, Ohashi R, Yoshida H, Naito Z.  Inhibitor for protein disulfide-isomerase family A member 3 enhances the antiproliferative effect of inhibitor for mechanistic target of rapamycin in liver cancer: An in vitro study on combination treatment with everolimus and 16F16  Oncol Lett  2021  21(1):28  PubMed ID: 33240434   DOI: 10.3892/ol.2020.12289
20105  Liang B, Zhou Y, Qian M, Xu M, Wang J, Zhang Y, Song X, Wang H, Lin S, Ren C, Monga SP, Wang B, Evert M, Chen Y, Chen X, Huang Z, Calvisi DF, Chen X.  TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.  J Hepatol  2021    PubMed ID: 33577921   DOI: 10.1016/j.jhep.2021.01.044
20136  El-Mezayen H, Yamamura K, Yusa T, Nakao Y, Uemura N, Kitamura F, Itoyama R, Yamao T, Higashi T, Hayashi H, Imai K, Chikamoto A, Yamashita YI, Baba H.  MicroRNA-25 Exerts an Oncogenic Function by Regulating the Ubiquitin Ligase Fbxw7 in Hepatocellular Carcinoma.  Ann Surg Oncol  2021    PubMed ID: 33886022   DOI: 10.1245/s10434-021-09778-2
14011  Wu Z, Kong X, Wang Z.  Integrin α7 knockdown suppresses cell proliferation, migration, invasion and EMT in hepatocellular carcinoma  Exp Ther Med  2021  21(4):309  PubMed ID: 33717252   DOI: 10.3892/etm.2021.9740
16100  Ogawa S, Kubo H, Murayama Y, Kubota T, Yubakami M, Matsumoto T, Yamamoto Y, Morimura R, Ikoma H, Okamoto K, Kamiya M, Urano Y, Otsuji E.  Rapid fluorescence imaging of human hepatocellular carcinoma using the β-galactosidase-activatable fluorescence probe SPiDER-βGal  Sci Rep  2021  11(1):1794  PubMed ID: 34504174   DOI: 10.1038/s41598-021-97073-1
12545  Aiyama T, Orimo T, Yokoo H, Ohata T, Hatanaka KC, Hatanaka Y, Fukai M, Kamiyama T, Taketomi A.  Adenomatous polyposis coli-binding protein end-binding 1 promotes hepatocellular carcinoma growth and metastasis  PLoS One  2020  15(9):e0239462  PubMed ID: 32956413   DOI: 10.1371/journal.pone.0239462
12313  Sato Y, Yamada T, Hiroyama T, Sudo K, Hasegawa N, Hyodo I, Nakamura Y.  A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li-7  Cancer Sci  2019  110(5):1644-1652  PubMed ID: 30784169   DOI: 10.1111/cas.13978
13423  Zhiyong Wu, Xiaoyu Kong, Zhihui Wang  Integrin α7 knockdown suppresses cell proliferation, migration, invasion and endothelium-mesenchymal transformation in hepatocellular carcinoma  Research Square  2019      DOI: 10.21203/rs.2.18036/v1
4276  Fujisaka Y, Iwata T, Tamai K, Nakamura M, Mochizuki M, Shibuya R, Yamaguchi K, Shimosegawa T, Satoh K.  Long non-coding RNA HOTAIR up-regulates chemokine (C-C motif) ligand 2 and promotes proliferation of macrophages and myeloid-derived suppressor cells in hepatocellular carcinoma cell lines.  Oncol Lett  2018    PubMed ID: 29387231   DOI: 10.3892/ol.2017.7322
5802  Eguchi T et al  Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment.  PLoS One  2018  13(2):e0191109.  PubMed ID: 29415026   DOI: 10.1371/journal.pone.0191109
10240  Ohata T, Yokoo H, Kamiyama T, Fukai M, Aiyama T, Hatanaka Y, Hatanaka K, Wakayama K, Orimo T, Kakisaka T, Kobayashi N, Matsuno Y, Taketomi A.  Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition.  Cancer Med  2017  6:1049-1061  PubMed ID: 28374947   DOI: 10.1002/cam4.1020
14269  Futami T, Okada H, Kihara R, Kawase T, Nakayama A, Suzuki T, Kameda M, Shindoh N, Terasaka T, Hirano M, Kuromitsu S.  ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma  Mol Cancer Ther  2017  16(1):68-7  PubMed ID: 27837028   DOI: 10.1158/1535-7163.MCT-16-0188
9574  Ferraris P, Chandra PK, Panigrahi R, Aboulnasr F, Chava S, Kurt R, Pawlotsky JM, Wilkens L, Osterlund P, Hartmann R, Balart LA, Wu T, Dash S.  Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.  Am. J. Pathol.  2016  186:938-51  PubMed ID: 26896692   DOI: 10.1016/j.ajpath.2015.11.027
9576  Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T.  Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.  Int. J. Oncol.  2016  48:1794-804  PubMed ID: 26936487   DOI: 10.3892/ijo.2016.3403
14010  Higashi T, Hayashi H, Kitano Y, Yamamura K, Kaida T, Arima K, Taki K, Nakagawa S, Okabe H, Nitta H, Imai K, Hashimoto D, Chikamoto A, Beppu T, Baba H.  Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma  Med Oncol  2016  33(11):123  PubMed ID: 27734263   DOI: 10.1007/s12032-016-0845-6
12536  Takeshi Yamada, Masato Abei, Inaho Danjoh, Ryoko Shirota, Taro Yamashita, Ichinosuke Hyodo, Yukio Nakamura  Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib  BMC Cancer  2015  15:260  PubMed ID: 25885470   DOI: 10.1186/s12885-015-1297-7
12537  Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T.  Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo  Int J Oncol  2015  46(6):2419-30  PubMed ID: 25823465   DOI: 10.3892/ijo.2015.2941
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196   DOI: 10.1111/hepr.12312
12542  Suzuki R, Aruga A, Kobayashi H, Yamato M, Yamamoto M.  Development of a novel in vivo cancer model using cell sheet engineering  Anticancer Res  2014  34(9):4747-54.  PubMed ID: 25202053  
12543  Kinoshita H, Okabe H, Beppu T, Chikamoto A, Hayashi H, Imai K, Mima K, Nakagawa S, Ishimoto T, Miyake K, Yokoyama N, Ishiko T, Baba H.  Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma  Oncol Rep  2013  29(2):685-9  PubMed ID: 23229496   DOI: 10.3892/or.2012.2162
12544  Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T.  Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma  Hepatol Res  2013  43(9):959-69  PubMed ID: 23369163   DOI: 10.1111/hepr.12047
12539  Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M, Arimori K.  Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells  Biol Pharm Bull  2012  35(3):400-7  PubMed ID: 22382328   DOI: 10.1248/bpb.35.400
5863  Yoshii Y, Waki A, Yoshida K, Kakezuka A, Kobayashi M, Namiki H, Kuroda Y, Kiyono Y, Yoshii H, Furukawa T, Asai T, Okazawa H, Gelovani JG, Fujibayashi Y.  The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation.  Biomaterials  2011  32(26):6052-8  PubMed ID: 21640378   DOI: 10.1016/j.biomaterials.2011.04.076
12540  Futami K, Ogasawara S, Goto H, Yano H, Furuichi Y.  RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma  Int J Mol Med  2010  25(4):537-45  PubMed ID: 20198302   DOI: 10.3892/ijmm_00000375
12546  Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K, Shinomura Y.  Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma  World J Gastroenterol  2010  16(28):3521-8  PubMed ID: 20653060   DOI: 10.3748/wjg.v16.i28.3521
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ